Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is set to release its earnings data after the market closes on Wednesday, July 31st. Persons interested in listening to the company’s earnings conference call can do so using this link.
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 0.90% and a negative net margin of 2.75%. The firm had revenue of $47.46 million for the quarter, compared to analysts’ expectations of $48.50 million.
Vanda Pharmaceuticals Trading Down 1.7 %
Shares of NASDAQ VNDA traded down $0.10 during midday trading on Tuesday, reaching $5.90. 120,286 shares of the company were exchanged, compared to its average volume of 1,655,992. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75. The stock has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $4.80. The stock has a market cap of $343.38 million, a P/E ratio of -75.00 and a beta of 0.75.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
- Five stocks we like better than Vanda Pharmaceuticals
- Utilities Stocks Explained – How and Why to Invest in Utilities
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- How to buy stock: A step-by-step guide for beginners
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.